Workshop: Beyond Viral Vectors: An End-to-End Platform for Rapid CAR-T and CAR-NK Generation
Are you exploring alternatives to viral vectors for cell engineering? Looking for ways to accelerate CAR-T and CAR-NK development while simplifying manufacturing workflows and reducing process complexity?
As the cell therapy field continues to evolve, next-generation non-viral approaches are emerging as powerful tools to address many of the challenges associated with traditional viral vector manufacturing. From plasmid engineering and mRNA optimization to mRNA production, purification, and immune cell engineering, integrated workflows are enabling faster, more flexible development of engineered immune cell therapies.
Join our experts as they discuss the latest advances in non-viral cell engineering technologies and explore how end-to-end platforms can streamline the generation of CAR-T and CAR-NK products, from early research through process development.
What to expect:
Our experts will explore key considerations and innovations in next-generation CAR-T and CAR-NK development, including:
- How to build a customizable end-to-end non-viral workflow spanning plasmid engineering, mRNA optimization, mRNA production, purification, and immune cell engineering through a single technology partner.
- How mRNA-based cell engineering can serve as an alternative to lentiviral workflows, reducing process complexity while enabling the rapid generation of engineered immune cells.
- Strategies for improving transfection outcomes in hard-to-engineer cell types, including both T cells and NK cells, using preformed vesicle-based delivery technology.
- Analytical and purification approaches that support the production of highly pure mRNA while minimizing process-related impurities.
